Zdrowie i gospodarka · 01/02/2019

FDA Announces Draft Guidance for Industry on Risk Evaluation and Mitigation Strategies Assessment

The Food and Drug Administration (FDA) has released a draft guidance document outlining how pharmaceutical companies should assess and report on the effectiveness of their risk evaluation and mitigation strategies (REMS) in meeting their risk mitigation goals, as part of the Prescription Drug User Fee Act V.